The Uromigos

Health EN ↓ Epizody: 485

Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Určitě navštivte web podcastu a podpořte jeho tvůrce: www.uromigos.org

Autor

The Uromigos

Kategorie

Health

Web podcastu

www.uromigos.org

Nejnovější epizoda

5. říj 2026

Kde poslouchat?

Podcasty v aplikaci Replaio Radio Už brzy

Podcasty míří do aplikace už brzy. Nainstaluj si ji teď a jako první uvidíš úplně nový pohled na podcasty

Nainstaluj zdarma Android téměř 10 mil. stažení · hodnocení 4,8 iOS už brzy

Epizody

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap 21.07.2025 27:49

Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.

Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials 14.07.2025 43:59

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers? 07.07.2025 45:46

Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

Episode 428: ASCO 2025 Recap 16.06.2025 54:20

Brian, Tom and Silke discuss their highlights form ASCO 2025

Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC) 13.06.2025 40:27

Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.

Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC 06.06.2025 37:22

Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025

Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI 04.06.2025 19:39

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session 02.06.2025 30:10

Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.

Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC 01.06.2025 30:49

Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

Episode 422: ACSO 2025 - ctDNA data from NIAGARA 01.06.2025 32:40

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer 01.06.2025 34:49

Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.

Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer 01.06.2025 24:18

Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation

Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study 31.05.2025 23:49

Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

Episode 418: ASCO 2025 - Biomarkers in RCC 31.05.2025 44:55

David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.

Episode 416: ASCO 2025 Preview 19.05.2025 40:43

Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025

Episode 413: The Uromigos Score for Advanced Prostate Cancer 12.05.2025 37:02

Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.

Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC 05.05.2025 28:52

Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1 05.05.2025 37:20

Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.

Episode 411: Live from EIKCS in Amsterdam - RCC Highlights 03.05.2025 20:26

Viktor Grunwald joins to discuss the new data session from EIKCS

Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC 26.04.2025 47:27

Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting

Episode 407: Drug Development in China: Part 2 of 2 21.04.2025 25:21

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

Episode 406: Drug Development in China: Part 1 of 2 14.04.2025 30:02

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

Episode 405: The Good News About Cancer podcast 11.04.2025 17:53

Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.

Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands 07.04.2025 27:09

Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.

Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands 02.04.2025 37:41

Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer